The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
|Videos|April 27, 2011
Dr. Edith Perez Discusses Her Ongoing Research
Author(s)Edith A. Perez, MD,
Advertisement
Edith A. Perez, MD, director of the Breast Program and professor of medicine at the Mayo Clinic discusses her ongoing research.
Advertisement
Related to this article
The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
Savolitinib received conditional NMPA approval in China for MET-amplified gastric or GEJ adenocarcinoma after prior systemic therapy, based on a 32.3% ORR.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
4
FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer
5